VAPESTICK comes out top in independent E-Cig study Source
(Thomson Reuters ONE) -
VAPESTICK, one of the UK's leading brands for electronic cigarettes, has
confirmed that its flagship product, the VAPESTICK MAX, was recently selected
for inclusion in an independent scientific study funded (and conducted on behalf
of) the UK's MHRA (Medicines and Healthcare Products Regulatory Agency).
The study was commissioned in order to examine the consistency of nicotine
levels within 5 of the major e-cigarette brands on the UK market today, and the
way in which they deliver nicotine to the user.
It was conducted by researchers from the 'Tobacco Dependence Research Unit' at
the Wolfson Institute of Preventative Medicine, Queen Mary University of London
UK, and the 'Department of Health Behaviour' at the Division of Cancer
Prevention and Population Sciences, Roswell Park Cancer Institute, Buffalo, USA
The study reported, "We selected the most popular UK brands, purchased two
samples of each four weeks apart, and analysed the products for nicotine content
in the cartridges and nicotine delivery in vapour."
VAPESTICK's MAX e-cigarette delivered the best results in both categories of the
study.
The 'mean difference between batches' of the nicotine levels found in the
VAPESTICK product was the best in the tested group, at just 0.3mg difference,
confirming that VAPESTICK's manufacturing and quality controls are of the
highest standards.
The results from the 'nicotine delivery tests' also demonstrated the high
performance and quality of VAPESTICK's e-cigarette hardware.
The MAX e-cigarette out-performed all the other market leaders in terms of its
consistent delivery of nicotine.
Michael Clapper, co-founder and chairman at VAPESTICK said, "We are of course
delighted with these results. These tests have shown that our commitment ECITA -
our industry body, has paid dividends when it comes to the superb levels of
consistency now found in our products."
The study's authors concluded that the acceptable variations found in many
medicinal products are often considerably greater than they found among the
electronic cigarette products tested. They concluded that there "does not seem
to be a need for any more burdensome regulation than that which already exists"
- except for "age restrictions on sales to minors."
VAPESTICK has been openly calling for a mandated age restriction since its
inception, and continues to want this to happen. Until that time VAPESTICK
voluntarily restricts the sales of its products to those under 18 years old.
Clapper said, "The factors tested in this study are exactly what our customers
are looking for from their e-cigarette, in order to successfully and permanently
make the switch away from the perils of smoking. We have a dedicated research
team who work hard to ensure that our e-cigarettes are made to the highest
possible standards. We have always believed in the quality and performance of
our products, and this study provides further indication that our assertions are
well founded."
The scientific study was funded by the UK's MHRA, who have declared their
preference to regulate e-cigarettes under a medicines regulatory framework.
VAPESTICK says that such a framework would be prohibitively expensive and would
most likely remove the majority of the existing industry in one stroke, thus
depriving consumers of the opportunity to reap the benefits of making the switch
away from smoking.
The study's authors concluded that a medicines framework would be unnecessary,
It said, "There is very little risk of nicotine toxicity from major electronic
cigarette (EC) brands in the United Kingdom."
Clapper added, "The existing regulations to which e-cigs must already comply,
enforced by Trading Standards and others, and codified by ECITA, are sufficient
to ensure that electronic cigarettes can indeed be of a very high quality, and
deliver what consumers want - as this study has revealed when examining the UK's
leading e-cigarette products."
Distributed by Pressat
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: The Vapestick Group Ltd via Thomson Reuters ONE
[HUG#1745005]
Unternehmensinformation / Kurzprofil:
Datum: 21.11.2013 - 17:25 Uhr
Sprache: Deutsch
News-ID 319318
Anzahl Zeichen: 4995
contact information:
Town:
Stanmore, Middlesex
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 121 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"VAPESTICK comes out top in independent E-Cig study Source"
steht unter der journalistisch-redaktionellen Verantwortung von
The Vapestick Group Ltd (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
